과제정보
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2017R1C1B5076980).
참고문헌
- Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr 2015;169:1053-60. https://doi.org/10.1001/jamapediatrics.2015.1982
- Kang B, Choe YH. Early biologic treatment in pediatric Crohn's disease: catching the therapeutic window of opportunity in early disease by treat-to-target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. https://doi.org/10.5223/pghn.2018.21.1.1
- Kang B, Choi SY, Kim HS, Kim K, Lee YM, Choe YH. Mucosal healing in paediatric patients with moderate-to-severe luminal crohn's disease under combined immunosuppression: escalation versus early treatment. J Crohns Colitis 2016;10:1279-86. https://doi.org/10.1093/ecco-jcc/jjw086
- Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009;330:864-75. https://doi.org/10.1124/jpet.109.153973
- Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710. https://doi.org/10.1056/NEJMoa1215734
- Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21. https://doi.org/10.1056/NEJMoa1215739
- Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization andEuropean Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. https://doi.org/10.1097/MPG.0000000000002035
- van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 2021;15:171-94. https://doi.org/10.1093/ecco-jcc/jjaa161
- Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. Intest Res 2018;16:4-16. https://doi.org/10.5217/ir.2018.16.1.4
- Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, et al. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. Intest Res 2018;16:17-25. https://doi.org/10.5217/ir.2018.16.1.17
- Lowenberg M, Vermeire S, Mostafavi N, Hoentjen F, Franchimont D, Bossuyt P, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn's disease. Gastroenterology 2019;157:997-1006. https://doi.org/10.1053/j.gastro.2019.05.067
- Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017;66:839-51. https://doi.org/10.1136/gutjnl-2015-311079
- Abreu C, Magro F, Santos-Antunes J, Pilao A, Rodrigues-Pinto E, Bernardes J, et al. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population. J Crohns Colitis 2013;7:e486-92. https://doi.org/10.1016/j.crohns.2013.03.004
- Ledder O, Assa A, Levine A, Escher JC, de Ridder L, Ruemmele F, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD porto group of ESPGHAN. J Crohns Colitis 2017;11: 1230-7. https://doi.org/10.1093/ecco-jcc/jjx082
- Singh N, Rabizadeh S, Jossen J, Pittman N, Check M, Hashemi G, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2016;22:2121-6. https://doi.org/10.1097/MIB.0000000000000865
- Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-27. https://doi.org/10.1053/j.gastro.2014.05.008
- Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, et al. Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's disease. Gastroenterology 2018;155:687-95. https://doi.org/10.1053/j.gastro.2018.05.039
- Pouillon L, Vermeire S, Bossuyt P. Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. BMC Med 2019;17:89. https://doi.org/10.1186/s12916-019-1323-8
- Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018;16:1937-46. https://doi.org/10.1016/j.cgh.2018.04.040
- Aardoom MA, Jongsma MM, de Vries A, Wolthoorn J, de Ridder L, Escher JC. Vedolizumab trough levels in children with anti-tumor necrosis factor refractory inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2020;71:501-7. https://doi.org/10.1097/MPG.0000000000002833